-
公开(公告)号：US20130137740A1
公开(公告)日：2013-05-30
申请号：US13695804
申请日：2011-05-05
IPC分类号： A61K31/4164 , A61N5/10 , A61K31/4178 , A61K45/06 , C07D233/58 , C07D403/10
CPC分类号： A61K31/4164 , A61K31/4178 , A61K31/42 , A61K45/06 , A61N5/10 , C07D233/58 , C07D233/64 , C07D263/32 , C07D403/04 , C07D403/10 , A61K2300/00
摘要： The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.
摘要翻译： 本发明涉及考布他汀特异性类似物，特别是本文所述和定义的式（I）化合物，以及包含该化合物的药物组合物及其医疗用途，特别是治疗或预防癌症，包括 多重耐药性癌症。
-
公开(公告)号：US20170197992A1
公开(公告)日：2017-07-13
申请号：US15326381
申请日：2015-07-13
申请人： Michael HÖPFNER , Bernhard BIERSACK , Rainer SCHOBERT , Katharina MAHAL , CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN , UNIVERSITÄT BAYREUTH
IPC分类号： C07F1/00 , C07D233/64
CPC分类号： C07F1/00 , C07D233/61 , C07D233/64 , C07F1/12
摘要： The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
-
公开(公告)号：US09868750B2
公开(公告)日：2018-01-16
申请号：US15326381
申请日：2015-07-13
申请人： CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN , UNIVERSITÄT BAYREUTH , Michael Höpfner , Bernhard Biersack , Rainer Schobert , Katharina Mahal
IPC分类号： C07F1/00 , C07D233/64
CPC分类号： C07F1/00 , C07D233/61 , C07D233/64 , C07F1/12
摘要： The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
-
公开(公告)号：US08980933B2
公开(公告)日：2015-03-17
申请号：US13695804
申请日：2011-05-05
IPC分类号： A61K31/4164 , A61K31/4178 , A61K31/42 , C07D233/64 , C07D263/32 , C07D403/04 , A61K45/06 , A61N5/10 , C07D233/58 , C07D403/10
CPC分类号： A61K31/4164 , A61K31/4178 , A61K31/42 , A61K45/06 , A61N5/10 , C07D233/58 , C07D233/64 , C07D263/32 , C07D403/04 , C07D403/10 , A61K2300/00
摘要： The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.
摘要翻译： 本发明涉及考布他汀特异性类似物，特别是本文所述和定义的式（I）化合物，以及包含该化合物的药物组合物及其医疗用途，特别是治疗或预防癌症，包括 多重耐药性癌症。
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
